Amarin Corporation PLC
AMRN.O- Latest Trade
- trading higher1.61USD
- Change
- 0
- % Change
0.00%
- As of Aug 12 2022. Values delayed up to 15 minutes
- Day Range
- -- - --
- 52-Week Range
- 1.11 - 5.97
- Previous Close
- 1.61
- Open
- 0.00
- Volume
- 25,863.00
- 3 Month Average Trading Volume
- 81.04
- Shares Out (Mil)
- 403.21
- Market Cap
- 616.90
- Forward P/E
- -8.11
- Dividend Yield
- -99,999.99
Key Statistics
3 mean rating - 8 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- 1.30
- Price To Book (Quarterly)
- 1.05
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -15.55
- Return On Equity (TTM)
- -9.91
2021 (millions USD)
About Amarin Corporation PLC (AMRN.O)
Company Information
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics for cardiovascular disease management. The Company operates through the development and commercialization of Vascepa segment. Its lead product, Vascepa (icosapent ethyl) capsule for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Address
Gemini House, Bartholomews WalkDUBLIN,
FK7 9JQ
Ireland
Industry
Biotechnology & Drugs
Executive Leadership
- Per Wold - Olsen
- Non-Executive Independent Chairman of the Board
- Karim Mikhail
- President, Chief Executive Officer, Director
- Thomas Charles Reilly
- Chief Financial Officer, Senior Vice President
- Jason Marks
- Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary
- Aaron D. Berg
- Executive Vice President, President - US
- Stephen B. Ketchum
- President - Research and Development, Senior Vice President, Chief Scientific Officer
- Lars G. Ekman
- Non-Executive Independent Director
- Erin S. Enright
- Non-Executive Independent Director
- Patrick J. O'Sullivan
- Non-Executive Independent Director
- Kristine Peterson
- Non-Executive Independent Director
- Jan G. Van Heek
- Non-Executive Independent Director
- Alfonso G. Zulueta
- Non-Executive Independent Director
Latest News
- BusinessAmarin to slash jobs as generic rivals dull U.S. prospects of heart drug
Amarin Corp Plc said on Monday it would cut its workforce by 40%, as the drugmaker's fish-oil derived heart drug faces stiff competition from generic rivals in the United States.
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,799.50 | 0.55%Positive |
| Copper | 676.30 | 0.70%Negative |
| Brent Crude Oil | 97.87 | 1.74%Negative |
| CBOT Soybeans | 1,691.50 | 1.05%Negative |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,265.15 | 1.38%Positive |
| Euro STOXX 50 | 3,776.81 | 0.53%Positive |
| FTSE 100 | 7,500.89 | 0.47%Positive |
| Nikkei 225 | 28,546.98 | 2.62%Positive |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes